Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
|
|
CEN BIOTECH INC (CENBF)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/06/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/29/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/16/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/07/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"CEN Biotech Inc. Shares To Commence Trading on the OTCQB Venture Market® Windsor, ON – September 7, 2022 – CEN Biotech Inc. , a global holding company focused on the development of leading-edge digital media technologies, LED lighting technology and hemp-based products announced that as of September 8, 2022, its common shares will begin trading on the OTCQB Venture Market® under the symbol "CENBF". The OTCQB Venture Market, operated by OTC Markets Group Inc., is for entrepreneurial and development stage U.S. and international companies. To be eligible to trade on the OTCQB Venture Market, companies must meet certain standards, including being current in their reporting obligations and undergoing an annual verification and management certification process. Companies must also meet $0.01 bid..." |
|
| 08/31/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN LAWRENCE LEHOUX AND CEN BIOTECH, INC.",
"EXECUTIVE EMPLOYMENT AGREEMENT BETWEEN BRIAN S. PAYNE AND CEN BIOTECH, INC.",
"CEN BIOTECH, INC. 2021 EQUITY COMPENSATION PLAN RESTRICTED STOCK AGREEMENT",
" ",
"CEN BIOTECH, INC. 2021 EQUITY COMPENSATION PLAN RESTRICTED STOCK AGREEMENT",
"CEN BIOTECH, INC. 2021 EQUITY COMPENSATION PLAN RESTRICTED STOCK AGREEMENT",
"CEN BIOTECH, INC. 2021 EQUITY COMPENSATION PLAN RESTRICTED STOCK AGREEMENT",
"CEN BIOTECH, INC. 2021 EQUITY COMPENSATION PLAN RESTRICTED STOCK AGREEMENT",
"CEN BIOTECH, INC. 2021 EQUITY COMPENSATION PLAN RESTRICTED STOCK AGREEMENT" |
|
| 08/22/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/20/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/05/2022 |
8-K
| Quarterly results |
| 04/21/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office... |
| 04/19/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"From:",
"From: Alex Tarrabain Sent: Thursday, April 14, 2022 7:48:23 PM To: Brian Payne Subject: Resignation Brian Payne, Effective immediately I, Alex Tarrabain, hereby resign from my position as Vice President & CFO of Cenbiotech Inc. I also resign from my duties as Director of the Board all other roles. I would like congratulate Brian Payne on his new role as CEO, CFO, Chairman of the Board and Principal Executive and Accounting Officer With kindest regards, Alex Tarrabain Work: 780-468-1898 Fax: 780-468-9354 Email: [email protected]",
"From:",
" ",
"From:" |
|
| 04/14/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 04/13/2022 |
4
| Purdy Rick Leigh (SVP of Deals and Acquisitions) has filed a Form 4 on CEN BIOTECH INC|
Txns:
| Granted 2,500,000 shares
@ $0 |
|
| 03/30/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 12/08/2021 |
8-K
| Quarterly results |
| 11/19/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/12/2021 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 10/13/2021 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...|
Docs:
|
"10.2",
"99.1*",
"CEN Biotech Inc. Announces the Closing of LED Patent Acquisition Windsor, ON – October 13, 2021 – CEN Biotech Inc. , a global holding company focused on the manufacturing, production and development of LED lighting technology and hemp-based products intended to help improve your state of health and well-being, is pleased to announce that it is has consummated the transaction for Patent Number U.S. 8,723,425 . On October 7, 2021, CEN entered into an Asset Purchase Agreement in connection with the purchase and acquisition of the right, title, and interest in and to the Patent, as more particularly described in the APA and related transaction documents. Pursuant to the Agreement, Tesla Digital, Inc., Tesla Digital Global Group, Inc. and Stevan Pokrajac are to receive 5,000,000 shares of CEN c..." |
|
| 09/17/2021 |
8-K/A
| Quarterly results |
| 08/30/2021 |
UPLOAD
| Form UPLOAD - SEC-generated letter: |
| 08/18/2021 |
10-Q/A
| Quarterly Report for the period ended June 30, 2021 [amend] |
| 08/13/2021 |
CORRESP
| Form CORRESP - Correspondence: |
| 08/12/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 08/02/2021 |
UPLOAD
| Form UPLOAD - SEC-generated letter: |
| 07/21/2021 |
3
| Lehoux Lawrence (Chief Technology Officer) has filed a Form 3 on CEN BIOTECH INC |
| 07/16/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 07/13/2021 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...|
Docs:
|
"Employment Agreement with Lawrence Lehoux",
"Audited Financial Statements of Clear Com Media Inc. for the years ended December 31, 2020 and 2019 and Unaudited Interim Financial Statements of Clear Com Media Inc. for the quarter ended March 31, 2021",
"CEN Biotech Inc. Announces Planned Strategic Expansion of Business and closing of Clear Com Media Inc. Acquisition Windsor, ON – July 12, 2021 – CEN Biotech Inc. , a global holding company focused on the manufacturing, production and development of LED lighting technology and hemp-based products intended to help improve your state of health and well-being, is pleased to announce that it is seeking to expand its business to include Cannabis, Psychedelic Mushrooms, and Digital Communities. CEN Biotech’s mission is to strive to be an agriculture based mindful provider of Phyto medical solutions developed to help improve "your" state of health and well-being. Our vision as a biotech company is to focus on Quality, Reliability and Transparency in all that we do while aiming to produce and deliv..." |
|
| 06/25/2021 |
SC 13D/A
| Tarrabain Alex reports a 6.5% stake in CEN BIOTECH, INC. |
| 06/25/2021 |
4
| Tarrabain Alex (CFO) has filed a Form 4 on CEN BIOTECH INC|
Txns:
| Granted 1,000,000 shares
@ $0
Acquired 3,000 shares
@ $0 |
|
|
|
|